PURPOSE: To investigate the influence of nanocarrier molecular size and shape on breast duct retention in normal rats using a non-invasive optical imaging method. METHODS: Fluorescein-labeled PEG nanocarriers of different molecular weights and shapes (linear, two-arm, four-arm, and eight-arm) were intraductally administered (50 nmol) to female Sprague-Dawley rats. Whole body images were obtained non-invasively. Fluorescence intensities (i.e., amount remaining in duct) were plotted against time to estimate the nanocarrier ductal retention half-lives (t(1/2)). Plasma samples were taken and the pharmacokinetics (Tmax, Cmax) of absorbed nanocarriers was also assessed. RESULTS: The t(1/2) of linear 12, 20, 30, 40, and two-arm 60 kDa nanocarriers were 6.7 ± 0.9, 16.1 ± 4.1, 16.6 ± 3.4, 21.5 ± 2.7, and 19.5 ± 6.1 h, whereas the four-arm 20, 40, and eight-arm 20 kDa had t(1/2) of 9.0 ± 0.5, 11.5 ± 1.9, and 12.6 ± 3.0 h. The t(1/2) of unconjugated fluorescein was significantly lower (14.5 ± 1.4 min). The Tmax for 12, 40, 60 kDa nanocarriers were 1, 24, and 32 h, respectively, and only 30 min for fluorescein. CONCLUSIONS: Since normal breast ducts are highly permeable, the use of nanocarriers may be helpful in prolonging ductal retention of diagnostic and/or therapeutic agents.
PURPOSE: To investigate the influence of nanocarrier molecular size and shape on breast duct retention in normal rats using a non-invasive optical imaging method. METHODS:Fluorescein-labeled PEG nanocarriers of different molecular weights and shapes (linear, two-arm, four-arm, and eight-arm) were intraductally administered (50 nmol) to female Sprague-Dawley rats. Whole body images were obtained non-invasively. Fluorescence intensities (i.e., amount remaining in duct) were plotted against time to estimate the nanocarrier ductal retention half-lives (t(1/2)). Plasma samples were taken and the pharmacokinetics (Tmax, Cmax) of absorbed nanocarriers was also assessed. RESULTS: The t(1/2) of linear 12, 20, 30, 40, and two-arm 60 kDa nanocarriers were 6.7 ± 0.9, 16.1 ± 4.1, 16.6 ± 3.4, 21.5 ± 2.7, and 19.5 ± 6.1 h, whereas the four-arm 20, 40, and eight-arm 20 kDa had t(1/2) of 9.0 ± 0.5, 11.5 ± 1.9, and 12.6 ± 3.0 h. The t(1/2) of unconjugated fluorescein was significantly lower (14.5 ± 1.4 min). The Tmax for 12, 40, 60 kDa nanocarriers were 1, 24, and 32 h, respectively, and only 30 min for fluorescein. CONCLUSIONS: Since normal breast ducts are highly permeable, the use of nanocarriers may be helpful in prolonging ductal retention of diagnostic and/or therapeutic agents.
Authors: Vered Stearns; Tsuyoshi Mori; Lisa K Jacobs; Nagi F Khouri; Edward Gabrielson; Takahiro Yoshida; Scott L Kominsky; David L Huso; Stacie Jeter; Penny Powers; Karineh Tarpinian; Regina J Brown; Julie R Lange; Michelle A Rudek; Zhe Zhang; Theodore N Tsangaris; Saraswati Sukumar Journal: Sci Transl Med Date: 2011-10-26 Impact factor: 17.956
Authors: Satoshi Murata; Scott L Kominsky; Mustafa Vali; Zhe Zhang; Elizabeth Garrett-Mayer; Dorian Korz; David Huso; Sharyn D Baker; James Barber; Elizabeth Jaffee; R Todd Reilly; Saraswati Sukumar Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: SivaNaga S Anumolu; Andrea S DeSantis; Anupa R Menjoge; Rita A Hahn; John A Beloni; Marion K Gordon; Patrick J Sinko Journal: Biomaterials Date: 2009-10-22 Impact factor: 12.479
Authors: John S Sundy; Michael A Becker; Herbert S B Baraf; Andre Barkhuizen; Larry W Moreland; William Huang; Royce W Waltrip; Allan N Maroli; Zeb Horowitz Journal: Arthritis Rheum Date: 2008-09
Authors: Amanda Migotto; Vanessa F M Carvalho; Giovanna C Salata; Fernanda W M da Silva; Chao Yun Irene Yan; Kelly Ishida; Leticia V Costa-Lotufo; Alexandre A Steiner; Luciana B Lopes Journal: Drug Deliv Date: 2018-11 Impact factor: 6.419